Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous
Pharma
Novartis tasks Lindy to turn biologics into at-home injectables
In a deal worth up to $954 million, Novartis will use Lindy’s suspension technology to design self-administered drugs against multiple targets.
Angus Liu
Aug 28, 2024 10:18am
Tracon seeks strategic options after injectable PD-L1 drug flop
Jul 2, 2024 4:32pm
ASCO surprise: J&J's injectable Rybrevant works better than IV
May 31, 2024 5:45pm
Roche touts near-complete MS suppression for injectable Ocrevus
Apr 17, 2024 11:00am
Eisai, Biogen's subQ Leqembi delayed amid FDA's data request
Apr 1, 2024 10:45am
BMS touts latest Opdivo data as I-O battle heads to new front
Jan 29, 2024 8:45am
